Fibrate class hypolipidemic drugs such as ciprofibrate activate the peroxisome proliferatoractivated receptor alpha (PPARα), which is involved in processes including lipid metabolism and hepatocyte proliferation in rodents. We examined the effects of ciprofibrate (50 mg/kg body weight per day for 60 days) on liver gene expression in rats using cDNA microarrays.
INTRODUCTION
Ciprofibrate belongs to fibrate class hypolipidemic drugs that are categorized as peroxisome proliferators (PPs). Peroxisome proliferators are a group of compounds that include fibrate hypolipidemic drugs and industrial chemicals such as phthalate ester plasticizers and herbicides (25) . In rodents, PPs have numerous effects including induction of peroxisome proliferation, β-oxidation, hepatocyte proliferation and hepatocarcinogenesis (16, 38, 42) .
These effects of PPs are mediated by peroxisome proliferator-activated receptor alpha (PPARα) (18, 40, 66) . PPARα is one of the three structurally related transcription factors, which are members of the steroid hormone receptor superfamily of ligand activated intracellular receptors (23, 31) . Peroxisome proliferator-activated receptors (PPARs) form heterodimers with retenoid receptor (RXR) and modulate transcription by binding to PPAR response elements (PPRE) in the promoters of their target genes (66) . The three PPAR isoforms PPARα, PPARβ/δ and PPARγ show distinct tissue expressions and ligand specificities (16, 20) . Ciprofibrate and other fibrate hypolipidemic drugs are selective PPARα ligands (22) . The role of PPARα in mediating the effects of PPs has been well illustrated by the absence of the classical pleiotropic effects such as hepatomegaly, peroxisome proliferation, and transcriptional-activation of target genes in PPARα knockout mice exposed to the compounds (40). Several studies have shown that PPARα activators are important in the transcriptional regulation of several genes involved in metabolism, hepatocyte proliferation, and immune modulation (16, 38) . Particularly well studied is the PPARα mediated transcriptional modulation of genes encoding enzymes of peroxisomal and mitochondrial fatty acid β-oxidation as well as genes encoding fatty acid transport proteins in rodent liver (16, 38) . PPARα agonists have also been shown to cause liver cancer in long-term exposures in rodents (53) . Although PPs are carcinogenic in rats and mice, there are marked species differences in responses, and these compounds have not been found to induce peroxisome proliferation and hepatocarcinogesis in humans (29) . The mechanism of the hepatocarcinogenic effect of PPARα activators in rats and mice is not well understood; however, it is thought to involve increased proliferation and oxidative stress induced by these compounds (4, 47) . For example, PPARα agonists such as ciprofibrate have been implicated in modulating the expression of some genes involved in cell proliferation such as cyclindependent kinases (CDKs) and cyclins (51, 56) . A previous study from our group has shown that 60-day dosing of rats with ciprofibrate induces a significant hepatocyte proliferation with increased liver weight, without established hepatocellular tumors (68) .
Recent studies using DNA microarray analysis have identified many novel genes regulated by PPARα in mice given short-term doses (for up to 2 weeks) with PPARα agonists (10, 34).
The aim of the present study was to identify ciprofibrate-regulated genes that may be important for liver growth, and to examine ciprofibrate effects on the diverse metabolic systems of the liver, in rats dosed sub-chronically (for 8 weeks) with ciprofibrate. This dosing period was chosen to elucidate both the metabolic and proliferative actions of ciprofibrate, while avoiding confounding effects from the hepatic carcinogenesis seen during more longterm stimulation. Using cDNAs microarrays of about 4900 genes, we show that ciprofibrate modulates many genes previously known to respond to PPARα agonists. Moreover, we identify novel potential targets of PPARα agonists including genes involved in metabolism, cell growth and proliferation, inflammatory responses, and oxidative stress responses.
MATERIALS AND METHODS
Reagents and Chemicals. Ciprofibrate (2-[4-(6-2,2 dichlorocyclopropyl) phenoloxyl]-2-methyl propionic acid) (Modalim) was purchased from Sanofi-Synthelabo (Alnwick, UK).
TRIZOLReagent was purchased from GIBCO BRL Life Technologies (New York, NY).
Radioisotope [α-
32 P] dCTP (3000 Ci/mmol) was from Amersham Biosciences (Little Chalfont, UK), and DNA polymerase (Klenow fragment) from Promega (Madison, WI).
SpotReport Array Validation System was purchased from Stratagene (La Jolla, CA).
Vectastain peroxidase-rabbit ABC (PK-4001) and a peroxidaze substrate kit (AEC SK4200)
were purchased from Vector Laboratories (Burlingame, CA).
Animals and Drug Administration. Fischer rats were purchased from Møllegaard's Breeding Center (Skensved, Denmark). Dosing of the animals with ciprofibrate was as described previously (5) . Briefly, female Fischer rats (200-250 g) were given tap water (control group) or ciprofibrate (50 mg/kg body weight), by gastric intubation, once daily for 60 days. The animals were then weighed, anesthetized (0.3 ml/100 g body weight of 2.5 mg/ml fluanison, 0.05 mg/ml fentanyl and 1.25 mg/ml midazolam), and killed by decapitation. The liver was removed in toto, weighed, and samples fixed on 4% phosphatebuffered formaline or homogenized for subsequent preparation of total RNA.
The study was approved by the Animal Welfare Committee at the University Hospital of Trondheim.
Histology and Immunohistochemistry. Formaline fixed tissue was embedded in paraffin and sectioned using routine histopathological methods. Histopathological examination was done on five randomly selected areas with hematoxylin-eosin stained sections. Immunostaining was performed using an antibody against the proliferation marker proliferating cell nuclear antigen (PCNA), avidin-biotin complex and peroxidase staining as previously 6 described (68). The number of proliferating hepatocytes and the total number of hepatocytes were determined in liver sections from 5 rats in each group, using a 250 by 250 µm ocular grid. Five randomly selected areas were counted on each section, and the results presented as the mean + standard error of the mean (SEM) of PCNA immunoreactive hepatocytes in percent of the total number of hepatocytes counted.
RNA Preparation. Fresh liver tissue was homogenized in a guanidinium-isothiocyanate buffer using an Ultra-Turrax rotating-knife homogenizer. Total RNA was isolated by ultracentrifugation on a cesium chloride cushion, and ethanol precipitated before further purification using TRIZOLReagent according to the manufacturer's protocols. The RNA quality and concentration was assessed by spectrophotometry and agarose gel electrophoresis. Microarray Hybridization. Hybridization experiments were performed using a pool of liver RNA from 5 control rats and RNA from each of 5 ciprofibrate dosed rats. One µg of total RNA from the control pool, and from each ciprofibrate dosed rat was reverse transcribed and labeled with Cy3-and Cy5-attached dendrimer, respectively, using 3DNA Array Detection Submicro kit as described in the manufacturer's protocols (Genisphere, Montvale, NJ).
Briefly, microarray slides were pre-hybridized in 1% BSA, 3. 
Database Submission of Microarray Data. The microarray data was prepared according to
Minimum Information About a Microarray Experiment (MIAME) recommendations (6) and deposited in Gene Expression Omnibus (GEO) database (19) , and can be accessed at http://www.ncbi.nlm.nih.gov/geo/. The GEO accession for the platform is GPL264. The four samples can be retrieved with GEO accessions GSM4676, GSM4677, GSM4678 and GSM4679, and constitute the series with GEO accession GSE335.
Northern Blot Analysis. DNA probes were made by amplifying cDNA inserts by PCR from plasmid clones using flanking M13 forward and M13 reverse primers. The PCR products were separated on agarose gel and purified using QIAQuick Gel Extraction kit (QIAGen, GmbH Max-Volmer-Strasse, Germany). The purified cDNA fragment was labeled using [α- Statistical Analysis. Group means were compared using t-test. p<0.05 was considered statistically significant.
RESULTS

Effects of Ciprofibrate on the Animals, Liver Weight and Proliferation Parameters.
Ciprofibrate dosing apparently did not influence the well-being of the animals. Body weight at the end of the experimental period was for controls 208.6 + 2.0 g (n=5) and for ciprofibratedosed rats 211.4 + 1.6 g (n=5) (mean + SEM) (p=0.31). Ciprofibrate induced a significant (p<0.001) 2.6 fold increase in total liver weight compared to controls, with no significant changes in liver architecture as assessed by routine light microscopy in hematoxylin-eosin stained sections. A corresponding significant (p <0.01) 2.1 fold increase in hepatocyte proliferation rate (% of PCNA-positive hepatocytes) was also observed in ciprofibrate dosed rats. These results are in agreement with previous reports (51, 68) .
Genes Differentially Regulated in Ciprofibrate Dosed
Rats. Genes differentially expressed in response to ciprofibrate were identified by microarray analysis by hybridizing RNA from 10 liver of dosed rats against a pool of RNA from liver of control rats. RNA from control rats was pooled because our goal was to identify genes differentially regulated in ciprofibrate dosed rats at levels over the background biological variability in the controls. Using a common reference or control is also the most commonly used design of microarray experiments, and has the advantage of allowing efficient comparison of samples (11) . Table 1 shows 90 known (named) genes annotated with processes that were considered to be of most interest in discussion of the pharmacological effects of PPARα ligands. The full list of the differentially regulated genes is available as supplementary data (Supplemental Table) . A total of 382 genes (222 named genes and 160 ESTs), representing about 8% of the genes on the array showed an average fold change in mRNA level of at least 1.4 (ratio ≥1.4 for upregulated or ≤ 0.7 for down-regulated genes) (Supplemental Table) . Of these, 249 (191 named genes and 58 ESTs) were up-regulated and 133 (31 named genes and 102 ESTs) were downregulated. The majority of the down-regulated genes (77%) are ESTs, while only 23% of the up-regulated genes are ESTs.
To facilitate interpretation of the results, the genes were grouped according to cellular processes in which they are likely to be involved, based on information from the literature, Swiss-Prot and LocusLink databases. Most the 268 genes representing 222 named genes and 46 ESTs annotated as "highly similar" or "moderately similar" to named genes could be grouped by cellular processes in this manner (Supplemental Table) . Even though many genes may be involved in more than one process, each gene was grouped into only one category.
Attempts were made to annotate a gene with the cellular process where it was considered most likely to belong in the context of pharmacological effects of PPARα agonists.
In order to choose fold change cutoff for differentially regulated genes, we compared fold changes obtained with the microarray method and Northern blot analysis (Fig. 1B) , and evaluated fold changes obtained for known PPARα regulated genes. The microarray protocol 11 we used tends to underestimate fold changes for differentially regulated genes compared to Northern blot analysis (Fig. 1B) . For example, 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 (Pfkfb1) with microarray ratio of 1.2±0.2 was found to be significantly (p<0.01) up-regulated with ratio 2.4±0.7, using Northern blot analysis (Fig. 1B) . Fold changes obtained by both methods were qualitatively similar, but microarray fold changes were lower than fold changes obtained by Northern blot for all the genes compared except Crmp1 (Fig. 1) .
Since the fold changes obtained by the microarray protocol we used were generally underestimated, we set the cutoff for differentially regulated genes to ≥1.4 fold. Although this threshold value may be considered low and some false positives are expected, our Northern blot analysis indicates that also false negatives occur and that a more stringent threshold would result in loss of valuable information.
Validation of Microarray Results by Northern Blot Hybridization and Exogenous RNA
Spikes. In this study, we used a microarray labeling and hybridization protocol that enables the use of very small amounts of RNA (63). We validated the microarray results using Northern blot analysis and by spiking labeling reactions with external RNA controls at predetermined ratios. For validation using Northern blotting, 11 genes with various levels of expression were selected and hybridized. Nine of the 11 probes tested by Northern hybridization gave detectable signals (Fig. 1A) . Two probes, bcl-2 associated death agonist (Bad) and bone morphogenetic protein-6 (Bmp6) did not give detectable signals by Northern hybridization (data not shown). All genes detected by Northern hybridization showed qualitatively similar expression changes in Northern blot and microarray analysis except one (Crmp1), that appeared to be up-regulated by microarray analysis, but was found to be unchanged by
Northern hybridization (Fig. 1) . However, for most genes, expression changes detected by microarray were underestimated by a factor of 1.5-5 compared to Northern blot analysis (Fig.   1 ). One gene (Cte1), showed very high quantitative discrepancy (about 30 fold) between the two methods (Fig. 1B) . The reason for the large deviation of Cte1 is not clear, but may be due to cross-hybridization of other genes with underestimation of the fold-change in cDNA microarray analysis. Importantly, although the fold changes are compressed in the microarray analysis, comparison with Northern blot analysis shows good qualitative agreement between the two methods for 8 out of 9 genes that could be detected. For example, even genes that changed less than two fold by Northern blotting (Crot and Ldha) could be detected as upregulated by microarray (Fig. 1) . One gene (Pfkfb1) with fold change 1.2, which is less than the threshold used for differentially regulated genes, showed significant (p≤0.01) change with Northern blotting. However, two other genes with microarray ratio of 1.2 (Cyp4a10) and 1.4
(Hmgcs1) were not significantly up-regulated by Northern blot analysis (Fig. 1) . Overall, about 70% of the genes (8 out of 11) tested by Northern blot analysis were confirmed, suggesting a false positive rate of up to 30% of the genes identified as differentially regulated by the microarray analysis. This is within the range of false positives commonly found in microarray experiments (8, 61) , and underlines that microarray results should be interpreted with some caution.
Further validation of our microarray protocol was done using Stratagene's SpotReport Array Validation System (Stratagene). Analysis of exogenous (Arabidopsis thaliana) poly (A)+ RNAs spiked into labeling reactions at predetermined ratios showed that the observed ratios highly correlate with the expected ratios (r=0.987) (Fig. 2) . The external controls also showed that a two fold change could be reliably detected and correlated well with expected fold changes (Fig. 2) . However, similar to Northern blot analysis, the observed fold changes for the external controls were also underestimated at both ends of the expected range (Fig. 2) .
DISCUSSION
In the present study, liver gene expression in rats sub-chronically dosed with the PPARα agonist ciprofibrate was analyzed using cDNA microarrays with probes representing 4908
genes. This drug increased liver weight and hepatocyte proliferation. Several known PPARα regulated genes and some potentially new targets, as well as indirectly affected non-target genes were differentially regulated in ciprofibrate dosed rats.
To validate microarray data, three procedures were performed: 1) Northern blot analysis of Table) , is most likely a false positive. Northern blotting results also suggest that both false positives and false negatives would be expected among the genes identified here to be differentially regulated. Thus, the genes identified here, particularly those with fold changes < 1.5, should be seen as candidates for differential regulation in ciprofibrate dosed rats. Further validation of the results should be done before firm conclusions are drawn regarding the biological mechanisms of the ciprofibrate effect on the rat liver.
Several studies have shown that PPARα regulates the expression of a number of genes involved in metabolism of lipids, glucose and amino acids (10, 16, 33, 34, 38) . In rodents,
PPARα agonists such as the hypolipidemic drug ciprofibrate are also known to induce hepatocyte proliferation, hepatocarcinogenesis (in long-term exposures), and immune modulation (16, 38) . The genes found to be differentially regulated here in ciprofibrate dosed rats are involved in a number of different cellular processes. In the following, some of these processes and the genes involved in them will be discussed.
Lipid Metabolism. Nearly all of the ciprofibrate induced genes grouped under lipid metabolism (Table 1A) Sugar Metabolism. Ciprofibrate up-regulated genes encoding enzymes that seem to be involved in sugar metabolism include lactate dehydrogenase A (Ldha) ( Table 1B , Fig. 1 ) and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 (Pfkfb1) (Fig. 1) . Pfkfb1 regulates phosphofructokinase, which constitutes an important control point in glycolysis (52) . The glucagon receptor (Gcgr), which is involved in regulation of blood glucose levels, was also up-regulated (Table 1B) 
Growth and Proliferation.
Several genes that appear to be involved in cell proliferation and related processes were found to be differentially expressed in ciprofibrate dosed rats (Table   1C) . This group represents genes not previously associated with responses to PPARα ligands.
Some of these genes also seem to have known roles in cell growth, proliferation and carcinogenesis. For example, nuclear protein 1 (Nupr1) that was up-regulated by ciprofibrate in the present study, has been shown to promote cell growth (44). Nupr1 is reported to be over-expressed in human pancreatic cancers and metastatic breast cancer cells (55, 64) , and has been found to be involved in induction of tumor development in transformed mouse embryo fibroblasts (67) . Other up-regulated genes in this category include the retinoblastoma-related gene (Rb2), involved in cell cycle regulation (39), ornithine decarboxylase (Odc1), the first rate-limiting enzyme in the synthesis of polyamines and often associated with increased proliferation and carcinogenesis (50) , and insulin-like growth factor 2 receptor (Igf2r), which is implicated in mitogenic and carcinogenic processes through its regulation of insulin-like growth factor 2 (60). Hras-revertant gene 107 (Hrev107), which was down-regulated in the present study, is a tumor suppressor and growth inhibitory gene reported to be up-regulated in fibroblasts that are resistant to transformation by H-ras oncogenes (27, 62). The changed expression patterns of a number of genes associated with cell growth and proliferation seem to agree with ciprofibrate induced hepatocyte proliferation and hepatomegaly observed here and in a previous study in our lab (68) . Although the mechanisms of the hepatocarcinogenic effects (in rodents) of PPARα ligands such as ciprofibrate are incompletely understood, induced alterations in expression levels of genes related to cell proliferation are thought to be contributing factors (26, 48, 51) . Thus, the cell growth and proliferation related genes represent good candidates for further confirmation and follow-up studies that may shed light on the mechanisms of hepatocarcinogenesis induced by PPs in rodents. It should be noted, however, that although the mechanism of the carcinogenic effects of PPs is not well understood, humans appear to be resistant to peroxisome proliferation and hepatocarcinogenic effects of these compounds (29) .
Stress Response. Several genes that appear to be related to stress responses were differentially regulated in the present study (Table 1D ). Fibrates and other PPs are known to increase H 2 O 2 levels leading to oxidative stress (21). It is therefore interesting to note that several genes known to be involved in the cells response to oxidative stress are up-regulated in ciprofibrate dosed rats (e.g. superoxide dismutase 3 (Sod3), copper-zinc-containing superoxide dismutase (Sod1), glutathione peroxidase 4 (Gpx4) and glutathione S-transferase, mu type 3 (Yb3) (Gstm3)) (Table 1D ). Another up-regulated gene in this category includes DNA -damage inducible transcript 3 (Ddit3), previously known to be induced by oxidative stress (43). In agreement with our results, copper-zinc-containing superoxide dismutase gene has been reported to be induced by bezafibrate in rat liver (30) . Clofibrate and other PPs were recently shown to increase the expression of base excision repair enzymes including Nmethylpurine-DNA glycosylase, DNA ligase I, and DNA polymerase β in rat and mouse liver (58) . In the present study, DNA polymerase β (Polb), replication factor C (Recc1) (Table 1C) and the DNA repair protein O6-methylguanine-DNA methyltranferase (Mgmt) (Table 1D) were up-regulated. Induction of these genes may be related both to increased proliferation and DNA damage repair. PPARα ligand induced elevation in H 2 O 2 levels leading to oxidative stress and DNA damage is thought to be one possible mechanism contributing to hepatocarcinogenesis in rodents (13, 26, 72) . Therefore, the differential expression of some of the stress related genes presented under this category may be related to oxidative stress responses.
Immune and Inflammatory Response. A role for PPARα in control of inflammatory responses has been suggested by the prolonged inflammatory responses observed in PPARα knockout mice (17) . Furthermore, modulation of acute-phase inflammatory response genes appears to be a PPARα dependent process (3). Thus, ciprofibrate-regulated genes associated with immune and inflammatory responses (Table 1E) have been reported to be positively or negatively regulated in response to pro-inflammatory cytokines (57) . Tf, α1-PI and Fgb are considered to be positive (up-regulated) acute-phase inflammatory response proteins in rats (57) . Thus, their down-regulation observed here and in other studies (12) appears to agree with the anti-inflammatory effects of PPARα (15) .
However, a2M that was up-regulated here (Table 1E ) and another alpha-macroglobulin family member, Mug1 down-regulated here (Fig. 1) , are thought to be positive and negative acutephase proteins, respectively (1, 57) . Adenosine A2a-receptor (Adora2a) and high mobility group1 (Hmgb1), which were up-regulated in the present study (Table 1E ) also appear to be involved in inflammatory responses (36, 37, 59). The results presented here provide many candidate genes that may increase further understanding of the immune modulatory effects of PPARα agonists.
Transcription. Transcription factors up-regulated in ciprofibrate dosed rats include hepatic nuclear factor-1 (Hnf1) and dimerization cofactor of Hnf1 ( Dcoh) ( Table 1F) . Hnf1 is known to participate in regulation of genes involved in lipid metabolism (2). Hnf1 and its transcriptional coactivator, Dcoh are also involved in the regulation of a number of other genes including some acute-phase inflammatory response genes described above (7, 14) . Two In addition to the group of genes discussed above several genes that may be involved in processes such as cytoskeletal organization, extracellular matrix formation, cell adhesion, signal transduction, steroid metabolism, protein metabolism, and ion transport were differentially regulated in ciprofibrate treated rats (Supplemental Table) . 
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